Atrium Therapeutics, Inc. 8K

Atrium Therapeutics received FDA clearance of its IND for ATR 1072, allowing initiation of the Corventis Phase 1/2 clinical trial for PRKAG2 syndrome.

Atrium Therapeutics, Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for ATR 1072, enabling the company to initiate Corventis, a Phase 1/2 open-label, multicenter clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ATR 1072 as a potentially disease-modifying RNA-based treatment for PRKAG2 syndrome, with site initiation underway, first patient enrollment expected by the end of 2026, and initial proof-of-concept data anticipated in the second half of 2027.

Filing Facts

CIK

2093101

Ticker

RNA

Form

8K

Source Type

fda

Accession

0001193125-26-303393

Alert Tier

6